BEAM THERAPEUTICS INC
BEAMNASDAQTrading Snapshot
- Day Range
- $24.22 – $24.79
- 52-Week Range
- $20.23 – $38.26
- Volume
- $2.81B
- Avg Volume
- $3.53B
- Shares Outstanding
- 102.9M
- Next Earnings
- Dec 9, 2026
Fundamentals Snapshot
- Annual Revenue
- $140M
- Last Q Revenue
- $490,000
- P/E Ratio
- -29.9
- P/S Ratio
- 16.2x
- EPS (TTM)
- $-0.82
- Dividend Yield
- 0.00%
- Dilution (1yr)
- +26.7%
Why Investors Own BEAM
- ✓High-growth profile — revenue up +4.6% YoY with expanding US Equity exposure.
- ✓Healthy economics — 43% gross margin and 26% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
BEAM THERAPEUTICS INC
BEAM
StockOtter · stockotter.spaceAbout BEAM THERAPEUTICS INC
Beam Therapeutics Inc., founded in 2017 and based in Cambridge, Massachusetts, operates as a pioneering biopharmaceutical firm. Its core mission involves engineering precise genetic remedies to tackle a spectrum of severe human ailments, primarily within the United States. The company's developmental portfolio features several key candidates: BEAM-101 is being advanced to treat both sickle cell disease and beta thalassemia. BEAM-102 is specifically designed for addressing sickle cell disease. BEAM-201, an allogeneic chimeric antigen receptor T-cell therapy, is under investigation for individuals suffering from relapsed or refractory T-cell acute lymphoblastic leukemia. BEAM-301 is a liver-targeted candidate aimed at patients afflicted with Glycogen Storage Disease Type Ia. Beyond these flagship programs, Beam Therapeutics is also engaged in devising treatments for alpha-1 antitrypsin deficiency, various ocular conditions, and other disorders impacting the liver, muscular system, and central nervous system. To further its research and development objectives, Beam Therapeutics has forged numerous strategic alliances and partnerships. These include collaborations with Boston Children's Hospital; a research and clinical trial agreement with Magenta Therapeutics, Inc.; a licensing deal with Sana Biotechnology, Inc.; and a research partnership with the Institute of Molecular and Clinical Ophthalmology Basel. Additionally, the company maintains research collaborations with both Pfizer Inc. and Apellis Pharmaceuticals, Inc., alongside a comprehensive collaboration and license agreement with Verve Therapeutics, Inc.
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)Analyst Price Target
ⓘLatest News & Updates
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Beam Therapeutics Inc. - BEAM
NEW YORK, Sept. 29, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Beam Therapeutics Inc. (“Beam” or the “Company”) (NASDAQ: BEAM). Such investors are advised to contact Daniell
Beam Therapeutics: Ignore The Anthropic Noise And Focus On Clinical Progress
Beam Therapeutics is reaffirmed as a long-term buy, with significant upside expected around 2028–2029 as BEAM-302 advances. BEAM's pipeline leadership in AATD gene editing (BEAM-302) offers first-mover advantage, while R
Squeeze Watch: 10 Stocks With Over 33% Short Interest
Ten stocks worth more than $2 billion each have more than a third of their float sold short. At the top of the list, one company has more than 80% of its float sold short.
Engineers Gate Manager LP Reduces Stock Holdings in Beam Therapeutics Inc. $BEAM
Engineers Gate Manager LP trimmed its position in shares of Beam Therapeutics Inc. (NASDAQ: BEAM) by 72.9% in the undefined quarter, according to the company in its most recent Form 13F filing with the Securities and Exc
BEAM Investors Have Opportunity to Join Beam Therapeutics Inc. Fraud Investigation with SBS Law
LOS ANGELES--(BUSINESS WIRE)---- $BEAM--BEAM Investors Have Opportunity to Join Beam Therapeutics Inc. Fraud Investigation with SBS Law.
These 10 Stocks Are Squeeze Candidates Waiting to Happen
Short sellers are making bold bets, and the numbers behind those bets are getting harder to ignore. Pessimism this concentrated can set the stage for sharp reversals, since a heavily shorted stock only needs a piece of g